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Abstract
Purpose: Recent safety issues involving medical devices have highlighted the need
for better postmarket surveillance (PMS) evaluation. This article aims to describe and
to assess the quality of the PMS data for a medical device and, finally, to provide
recommendations to improve the data gathering process.
Methods: A descriptive analysis of medical device reports (MDRs) on the use of
MRA, a specific type of hip implant replacement submitted to the Food and Drug
Administration Manufacturer and User Facility Device Experience database from
1 January 2008 to 31 December 2017. The number of reports was described as the
number of MDRs per unique MDR number and stratified by different variables. The
quality was assessed by the level of completeness of the collected PMS data.
Results: The total number of reports related to MRA was 2377, and the number of
MDRs per year ranged between 84 in 2009 and 452 in 2017. Most of the reports
were reported by manufacturer Depuy Johnson & Johnson and were reported by a
physician. In 44.9% of the reports, the device problem was reported as “Unknown.”
When the device problem was known, in the majority of cases, it was related to an
implant fracture. The quality of the collected data was assessed as low due to missing
information.
Conclusion: The underlying data should meet high quality standards to generate
more evidence and to ensure a timely signal generation. This case study shows that
the completeness and quality of the MDRs can be improved. The authors propose
the development of tools to ensure a more dynamic complaint data collection to con-
tribute to this enhancement.
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1 | INTRODUCTION
An implantable medical device is a device that is partly or totally
inserted into the human body or a natural orifice or is used to replace
the surface of the body and is expected to stay in use for 30 days or
more. Examples of implantable medical devices include dental
implants, breast implants, hip implants and intraocular lenses. Surgical
or medical procedures are used to insert, apply and remove implant-
able medical devices. To be classified as a non-active implantable
medical device (NAIMD), the medical device should not have an inte-
gral power source; all devices with a power source are considered
active implantable medical devices (eg, pacemaker, cochlear
implants…).1
Recent safety issues involving NAIMD have highlighted the need
for better premarketing and postmarketing evaluation.2,3 In the metal-
on-metal (MoM) hip safety issue, thousands of patients around the
world may have been exposed to high levels of toxic metals from failing
hip implants. The chromium and cobalt ions from the MoM hip implants
could enter into the tissues of patients with this type of hip implants,
leading to reactions that damaged the muscle and bone, and led to revi-
sion procedures or left some patients with long-term disability.4-7 This
safety issue was only identified by the Australian Health Authorities
upon review of the Australian Orthopaedic Association National Joint
Replacement Registry, and this finding was confirmed by the National
Joint Replacement Registry of England, Wales, and Northern Ireland
and the New Zealand Registry. This resulted in a worldwide recall of
the MoM hip implants. The safety issue was highly publicized as MoM
hip implants were approved for market use although lacking data
derived from clinical trials. In addition, the manufacturers did not effec-
tively review post-market clinical data (including device registries con-
taining postmarket surveillance information) and thus failed to identify
and report this risk to the health authorities.8
A prior safety issue with Poly Implant Prothesis breast implant
scandal3 had also contributed to the emerging growing demand to
improve the current passive-reactive postmarket surveillance (PMS)
system of medical devices. An important part of this PMS system is
the data collection of case (complaint) reports. To enhance the current
surveillance system, it is important to measure and assess the quantity
and quality of PMS data on medical devices.
Hip implants are NAIMD that are implanted during hip replace-
ment surgery. Hip replacement surgery can be performed traditionally
or by means of a minimally invasive technique. The main difference
between the two procedures is the size of the incision and the type of
prosthetic implant, either a total hip replacement or an MoM hip
replacement.9 With approximately 1.4 million hip implant surgeries
performed every year around the world, it is the most common joint
replacement procedure. In the United States, over 231 000 surgeries
are performed annually.10
Given the large use of hip implants and the need to improve med-
ical device vigilance, we performed a case study and conducted a
descriptive analysis of the PMS data from one of the most important
publicly available spontaneous reports database,11 the Food and Drug
Administration's (FDA) Manufacturer and User Facility Device
Experience (MAUDE) database, to assess the quality and the quantity
of these spontaneous reports using hip implants as a proof of concept,
but our aim was not to investigate and compare the safety of individ-
ual (or specific) implants.
2 | METHODS
2.1 | Data Source
The PMS data for hip implants were extracted from the FDA MAUDE
database. Medical device reports (MDRs) on the use of hip implant
replacement were extracted from the FDA MAUDE of MDRs received
by the FDA between 1 January 2008 and 31 December 2017.
MAUDE contains MDRs received by the FDA on worldwide complaint
data. Adverse events or technical complaint information of medical
devices can be reported to the FDA via user facility (hospital), con-
sumer or manufacturer.
Manufacturers must submit MDRs to the FDA “when they become
aware of information that reasonably suggests that one of their marketed
devices may have caused or contributed to a death or serious injury or
has malfunctioned and the malfunction of the device or a similar device
that they market would be likely to cause or contribute to a death or seri-
ous injury if the malfunction were to recur. Manufacturers must send
MDRs of such deaths, serious injuries and malfunctions to the FDA”12
when they become aware of any of the events described above
reported from any country in the world. The definition of serious
injury is described below.
The FDA provides access to MAUDE information through three
different tools: (a) an online simple (single-parameter) interface,
(b) advanced (multiparameter) search interface or (c) downloadable
data files. These online search engines are extremely convenient;
however, information obtained using these interfaces has some
restrictions.12-14 In our study, we used both the online search inter-
face and the downloadable datasets.
2.2 | Outcomes
For this study, we were interested in reports related to the use of
another type of hip implant (different from the MoM implant): the hip
joint metal/ceramic/ceramic/metal semiconstrained cemented or
uncemented prosthesis (FDA product code: MRA).15 We considered
Key Points
• The completeness and the quality of the data included in
the medical device reports can be improved.
• New standards and safety tools should be developed to
ensure a more dynamic complaint data collection process.
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all events related to this type of device as events of interest. The FDA
has a standardized vocabulary for adverse events and product prob-
lems. A total of 167 different event codes related to the use of the
hip implant of interest (MRA) were analyzed. Malfunctions and serious
injuries were classified according to the FDA regulatory definitions16;
a serious injury is an injury or illness that is life-threatening, results in
permanent impairment/damage or necessitates medical/surgical inter-
vention to preclude permanent impairment/damage. A malfunction
stands for the failure of a device to meet its performance specifica-
tions or to perform as intended [Performance specifications include all
claims made in the labeling of the device. The intended performance
of a device refers to the intended use for which the device is labeled
or marketed16].
The type of reporter was classified as unknown or known (physi-
cian, nurse, patient, pharmacist, administrative and known others).
The type of reported adverse events was classified as malfunction
and/or serious injury (for definitions, see above). The complaint sam-
ple availability and the corrective/remedial actions field were classi-
fied as Yes, No or NA.
2.3 | Data management and analysis
The study period comprised 10 years, and data for this period
(1 January 2008 through 31 December 2017) were obtained from
three MAUDE downloadable datasets: the MDR Freedom of Informa-
tion (FOI) master dataset, the Device Data dataset and the FOI Device
Problem dataset. The advanced search interface dataset was used to
obtain the name of all MRA hip implant manufacturers (filtering by
date on which the report was received by the FDA (1 January 2008
through 31 December 2017) and product code MRA) with reported
MDRs. The advanced search interface dataset was used to obtain the
name of all MRA hip implant manufacturers. We had to standardize
the manufacturer names by classifying each of the names from the
manufacturer's column into eight different categories: Depuy John-
son & Johnson, Stryker, Wright Medical Technology, Zimmer, Encore,
Stelkast, Exactech and Smith & Nephew.
We obtained the following information from each of the down-
loadable datasets:
• The MDR FOI Master dataset, filtering by the “manufacturer name”
field for all the MRA Hip Implant Manufacturers available. The fol-
lowing variables were used: MDR report key, manufacturer name,
type of event, report source, source type (country of origin; United
States or foreign), reporter occupation, remedial actions and
recalls.
• The Device Data dataset, filtering by “MDR report key.” The fol-
lowing variables were used from this dataset: MDR report key
number (to link), device availability and device evaluated by the
manufacturer.
• The FOI Device Problem dataset, filtering by “MDR report key.”
The following information was used from this dataset: MDR report
key Device Problem codes.
From these three datasets, one unique dataset was built using the
“MDR report key,” which was available in the three downloadable
datasets.
The data were analyzed using descriptive statistics, reporting
counts, proportions and stratifications. Absolute numbers and per-
centages were described by manufacturer, brand name, type of event
(death, injury, malfunction, NA, other), reporter's occupation, type of
reported adverse events and product problems, complaint sample
availability (whether the device is available for further investigation)
and corrective/remedial actions. The numerator was the number of
reports with MRA hip implants for a specific brand name, and the
denominator was the total number of reports for MRA hip implants
during the study period.
3 | RESULTS
Eight MRA hip implant manufacturers reported MDRs to the FDA:
Depuy Johnson & Johnson, Stryker, Wright Medical Technology,
Zimmer, Encore, Stelkast, Exactech and Smith & Nephew. A total of
2377 unique FDA-reportable complaints for MRA hip implants were
received by the FDA from the manufacturer between 1 January 2008
and 31 December 2017, mostly originating in the United States (1807
reports, 76.0%). There was a high percentage of missing information.
The proportion of reports with information on the type of device
problem was 55.1% (in 44.9% of the reports, the device problem was
reported as “Unknown”). The most frequently reported device prob-
lems included “implant fracture” (39.57%, 518 reports), “dislocation”
(11.38%, 149 reports), “loss of osseointegration” (8.40%, 110 reports),
“component/fitting issue” (2.60%, 34 reports),” material corrosion”
(1.91%, 25 reports) and “metal shedding debris” (0.61%, 8 reports)
(Table 1).
Compared to all other MRA hip implant manufacturers, Depuy
Johnson & Johnson had the most MDRs (64.28%, 1528 reports). For
the other manufacturers, the number of reports for MRA hip implants
were as follows: Stryker (22.97%, 546 reports), Wright Medical Tech
(8.08%, 192 reports), Smith & Nephew (1.94%, 46 reports), Zimmer
(1.77%, 42 reports), Exactech (0.51%, 12 reports), Encore Medical
(0.34%, 8 reports) and Stelkast (0.13%, 3 reports). Death occurred in
0.08% (2 reports), and serious injury occurred in 72.11% (1714
reports) (Table 1). The number of yearly MDRs increased from 84 in
2009 to 452 in 2017 (Figure 1).
The reporter's occupation was reported in 94.9% of all reports, of
which 40.5% of reporters were physicians (Table 1); 100% of the
reports were submitted by the manufacturer, and no reports were
submitted directly to the FDA by physicians, nurses, other healthcare
providers or patients.
The proportion of reports with information on the suspect
device availability was higher (98.57%, 2343 reports), and the device
was only available in 26.38% of the reports (627 reports). The manu-
facturer was only able to evaluate the suspect sample in 17.80% of
the reports (423 reports). Without a sample, it is more difficult to
identify the root cause of the event and take appropriate actions.
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TABLE 1 Overview of the characteristics of medical device reporting (MDR) data reported between 1 January 2008 and 31 December 2017
Manufacturer Number of MDRs (% of total)
Depuy Johnson & Johnson 1528 (64.28)
Stryker 546 (22.97)
Wright Medical Technology 192 (8.08)
Smith & Nephew 46 (1.94)
Zimmer 42 (1.77)
Exactech 12 (0.51)
Encore Medical 8 (0.34)
Stelkast 3 (0.13)
Device Problem
Known 1309 (55.07)
Unknown 1068 (44.93)
Known Device Problem n = 1309
Fracture/break/crack/scratched material 518 (39.57)
Dislodged/dislocated/displaced/disassembly/malposition/migration or expulsion of device 149 (11.38)
Loss of osseointegration/failure to bond 110 (8.40)
Component issue/connection issue/implant loose fitting issues/inadequacy of device shape/size/ 34 (2.60)
Material corrosion/degradation/integrity/deformation/naturally worn 25 (1.91)
Metal shedding debris 8 (0.61)
Other 465 (35.52)
Type of Event
Death 2 (0.08)
Serious injury 1714 (72.11)
Malfunction (no serious injury) 653 (27.47)
Other 4 (0.17)
Unknown 4 (0.17)
Country of Origin
United States 1807 (76.02)
Foreign (rest of the world excluding United States) 514 (21.62)
Unknown 56 (2.36)
Report Source Code
Manufacturer 2377
User facility 0
Distributor 0
Voluntary 0
Reporter Occupation
Physician 913 (38.41)
Health professional other than physician 445 (18.72)
Attorney 89 (3.75)
Patient 28 (1.94)
Risk manager 14 (1.77)
Pharmacist 7 (0.30)
Company technician/representative 7 (0.30)
Others 752 (31.64)
Unknown 122 (5.13)
(Continues)
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A remedial action was only identified for 26.67% (634 reports) of
the reports, and only 0.47% (3 reports) of the remedial actions were
associated with a recall. The three reports associated with a recall
came from the same manufacturer, namely, Depuy Johnson & John-
son (Table 1).
4 | DISCUSSION
This case study on medical device reporting on MRA hip implants to
the FDA demonstrated some key findings. First, beyond the United
States, very few reports were received from other countries, and no
reports were submitted by physicians, nurses, other healthcare pro-
viders or patients. Second, most reports were on serious injury, and
the most frequently reported device problem was “fracture of the hip
implant.” Third, completeness of information in the reports was poor,
and often, the suspect sample was not sent to the manufacturer and
therefore could not be evaluated, which hampers the root cause
analysis.
These results underline the need to obtain better postmarket
complaint data for medical devices within the United States and
beyond (Figure 2). Improvements can be made in the reporting itself,
TABLE 1 (Continued)
Manufacturer Number of MDRs (% of total)
Device Availability
Yes 627 (26.38)
No 1716(77.19)
Unknown 34 (1.43)
Device Evaluated by Manucturera (out of the available devices)
Yes 423 (67.46)
No 88 (14.04)
Unknown 116 (18.50)
Remedial Action
Other 630 (39.12)
Recall 3 (0.12)
Modification/adjustment 1 (0.04)
Blank 1743 (73.33)
Recalls-Removal Correction Number
Z-1749/1816-2011 (Depuy Johnson & Johnson) 2 (66.67)
Blank (Depuy Johnson & Johnson) 1 (33.33)
aThe device can only be evaluated by the manufacturer if it is available.
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F IGURE 1 Number of medical device reports related to MRA hip implant by manufacturer per year from 1 January 2008 to
31 December 2017
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the collecting database and the awareness of the different stake-
holders involved in the safety evaluation process. High quality stan-
dards with a consistent and structured approach are needed to
optimally gather MDR. More specificity in regulatory reporting and
harmonized regulatory coding might help to generate better evi-
dence to ensure an accurate and well-timed signal generation.
To address this problem of quality issues in reporting, as well as
in the completeness of data, the manufacturer and the health authori-
ties should engage the reporter (patient or healthcare professional) in
the complaint data collection process. In addition, the regulators and
the manufacturers could provide tools to healthcare providers and
users that would give more guidance on complaint reporting and
appropriate coding. Examples of such tools could be the development
of educational material for the healthcare professionals about com-
plaint reporting, including a list of key fields to be completed by the
reporter; guidance providing instructions on how to manipulate com-
plaint samples that have been in contact with human fluids and how
to return them to the manufacturer, ensuring safe transport to main-
tain the integrity of the complaint sample; the regulatory coding har-
monization and global implementation across jurisdictions; and coding
guidelines developed by the regulators for each type of medical
device and provided to all the stakeholders.
TABLE 2 Recommendations to improve Medical Device Reporting (MDR) and the Manufacturer and User Facility Device Experience
(MAUDE) database
Limitation Recommendation Owner
Event coding • Impossibility to identify patient harms and
root causes associated with specific FDA
device problem codes.
• FDA patient codes and FDA investigational
codes (methods, results and conclusions)
publicly available in MAUDE.
• FDA
Patient exposure • Lack of information about frequency of
device use does not allow to estimate patient
exposure.
• The manufacturers could make their
distribution/sales data available to the Health
Authorities, upon request.
• Global Health
Authorities
(including FDA),
Manufacturers
Root cause
identification
• For the majority of reports the suspect
sample is not available and cannot be
evaluated by the manufacturer. Identifying
the root cause of the event is especially
difficult if the device in question has not been
identified and directly evaluated by the
manufacturer.
• Global adoption of UDI: in order to identify
the device and link the device to a serial
number, UDI needs to be present on the
device and readily accessible in the medical
record.
• More guidance and training for the healthcare
professionals on the importance of sending
the device with all the adequate information
(including UDI) to the manufacturer for
evaluation, if the suspect device is explanted.
• Reporting facilities,
FDA, Manufacturers
Timely reporting • The MAUDE advanced search interface is
updated monthly, and the search page reveals
the date of the latest update. The FDA tries
to include all reports received before the
update, but the inclusion of some reports may
be delayed.
• More guidance and training on the
importance of timely reporting should be
provided to the different stakeholders
involved in the complaint handling process.
• Reporting facilities
Report source • Most of the MDRs from MAUDE come from
spontaneous reports received from the
manufacturer. This type of report may be
associated with reporting bias.
• Healthcare provider reports directly to the
FDA need to be strongly encouraged via
training and regulatory guidelines.
• Enriching the FDA MAUDE PMS data with
data from medical device registries. In order
to be able to link the registry data with the
manufacturer reports data, common
standardized dataset including UDI should be
created.
• FDA
Scope • MAUDE only includes FDA-reportable
complaints. If the complaint does not meet
the FDA reporting criteria, the complaint will
not be in MAUDE.
• MAUDE only includes complaints associated
with medical devices that are marketed in the
United States. If the medical device is not
marketed in the United States, the complaint
will not be in MAUDE.
• Exchange of PMS data (including FDA-
nonreportable complaints and trend reports
for FDA-nonreportable complaints) between
different Health Authorities.
• Development of a global repository to store
global PMS data for medical devices.
• IMDRF, Global Health
Authorities
(including FDA)
Abbreviations: FDA, Food and Drug Administration; PMS, PostMarket Surveillance; UDI, Unique Device Identifier.
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To stimulate reporting and facilitate timely reporting, the pro-
cess should be automated, and healthcare professionals could be
involved in the use of digital reporting tools such as mobile applica-
tions, online questionnaires, personalized forms and global elec-
tronic reporting of individual cases and aggregate reports, which
can lead to quality improvement of the collected information.17
Table 2 provides recommendations not only on how to improve
MDR reporting but also recommendations on how to improve data
collection in the MAUDE database. In addition to the limitations
described in Table 2, our results also have additional limitations as
postmarketing complaint data is prone to reporting bias.18 Moreover,
a descriptive analysis of postmarketing complaint data does not
allow to control patient predisposing factors such as family history,
health condition or previous surgeries. Therefore, we recommend
enriching the FDA MAUDE data with PMS data from medical device
registries. To link the registry data with the spontaneous report data
from MAUDE, a common Unique Device Identifier (UDI) should be
created. The UDI enables the unequivocal identification of the medi-
cal device by providing a single global identifier that can be used to
link and integrate the existing FDA MAUDE database with medical
device registries.19 The global use of a UDI facilitates traceability
throughout distribution and allows the recording of medical devices
used in patients. The UDI makes it possible to link patient, device
and adverse event/product problem and/or related data repositories.
This information can help the different stakeholders involved in the
safety evaluation of medical devices to quickly gather and evaluate
spontaneous reports or data from registries and act accordingly.
To improve the ability to signal problems on a global scale, a
global harmonization and repository/database (similar to the World
Health Organization [WHO] Vigibase for medicinal products) should
be created to allow sharing of information across the different
stakeholders (health authorities, users, manufacturers, notified bod-
ies and health professionals) in addition to the development of qual-
ity standards for the data gathering and a global centralized
database to collect and store reports related to medical devices. To
ensure success, regulators should partner with the manufacturers,
which could be facilitated by the improvement of worldwide interac-
tions between different stakeholders with support from the WHO,
International Council for Harmonization of Technical Requirements
for Pharmaceuticals for Human Use (ICH), Council for International
Organizations of Medical Sciences (CIOMS) and the International
Medical Device Regulators Forum (IMDRF). WHO, ICH and CIOMS
should provide their experience and lessons learned from the global
harmonization of medicinal products, and IMDRF should play a sig-
nificant role in the standardization of quality standards across the
different regulatory bodies.20
In conclusion, there is an urgent need for better PMS for medi-
cal devices, which we demonstrate through the MRA hip implant
Gather data in a 
consistent and 
structured manner
More guidance on 
complaint reporng 
and coding speciﬁcity in 
regulatory reporng
Automaon
• Implement a centralized system that would allow data
sharing across the diﬀerent stakeholders
• Develop guidelines for quality standards for the data
collecon process
• Engage all stakeholders to beer communicate post-market
surveillance data
• Global adopon of UDI
• Regulatory Coding harmonizaon (ISO, FDA)
• Develop coding guidelines for each type of medical device
• Provide coding trainings to all stakeholders involved
• Develop educaonal materials about complaint reporng,
including a list of key ﬁelds to be completed by the reporter
• Guidance on how to maintain the integrity of the complaint
sample and return it to the manufacturer
• Improvement of global interacon with the support from WHO
and IMDRF
• Mobile reporng applicaon
• Online quesonnaires
• Personalized forms
• Global electronic reporng of individual cases and
aggregate reports
F IGURE 2 Recommendations to obtain better postmarket complaint data for medical devices. FDA, Food and Drug Administration; IMDRF,
International Medical Device Regulators Forum; ISO, International Organization for Standardization; UDI, Unique Device Identifier; WHO, World
Health Organization
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example. The quality of postmarket complaint data and their timely
collection are crucial for the validity of the complaint reports. It is
time to face current challenges such as the lack of quality stan-
dards, lack of specificity in regulatory reporting, lack of harmonized
coding and lack of engagement from reporters at the time to send
samples back for analysis. We recommend that the different
stakeholders in this process (manufacturers, health authorities,
healthcare professionals and patients) work together to overcome
these challenges.
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